- Stocks
- Pharma & Healthcare
- Marksans Pharma
Marksans Pharma share price
NSE: MARKSANSPharma & HealthcareDrug Manufacturers - General
Marksans Pharma at a glance
Marksans Pharma (NSE: MARKSANS) closed at ₹295.80 on 22 Oct 2026, down 0.89% on the day. With a market capitalisation of ₹13,343 Cr, it ranks 469th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 32.1× trailing earnings, against a return on equity of 13.8% in FY26. Over the past year the share price has risen 62.6%. Its 52-week range is ₹155.00 (30 Mar 2026) to ₹350.95 (24 Sep 2026); the last close is 15.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹856 Cr (+20.8% year on year) and net profit ₹149 Cr (+64.3%), on a consolidated basis. Promoters held 43.87% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹13,343 CrRank 469 on NSE
- P/E (trailing)
- 32.1×
- Price to book
- 2.36×FY26
- EPS (TTM)
- ₹9.23to Q4 FY26
- ROE
- 13.8%FY26
- ROCE
- 17.5%FY26
- Debt to equity
- 0.01FY26
- Net profit margin
- 14.2%FY26
- Book value / share
- ₹66.71FY26
- 52-week high
- ₹350.9524 Sep 2026
- 52-week low
- ₹155.0030 Mar 2026
- 1-year return
- +62.6%
- RSI (14-day)
- 37.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.89% | −5.8% | −12.5% | +22.2% | +62.6% |
Marksans Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹591 Cr | ₹642 Cr | ₹682 Cr | ₹708 Cr | ₹620 Cr | ₹720 Cr | ₹754 Cr | ₹856 Cr |
| Revenue YoY | +18.1% | +20.8% | +16.3% | +26.5% | +5.0% | +12.2% | +10.6% | +20.8% |
| Net profit | ₹89 Cr | ₹98 Cr | ₹105 Cr | ₹91 Cr | ₹58 Cr | ₹99 Cr | ₹114 Cr | ₹149 Cr |
| Net profit YoY | +26.4% | +16.6% | +26.6% | +16.9% | −34.7% | +1.4% | +8.2% | +64.3% |
| Net margin | 15.1% | 15.2% | 15.4% | 12.8% | 9.4% | 13.8% | 15.1% | 17.4% |
| EPS | ₹1.96 | ₹2.13 | ₹2.31 | ₹2.00 | ₹1.29 | ₹2.17 | ₹2.50 | ₹3.27 |
Marksans Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,376 Cr | ₹1,491 Cr | ₹1,852 Cr | ₹2,177 Cr | ₹2,623 Cr | — |
| Operating profit | ₹302 Cr | ₹248 Cr | ₹338 Cr | ₹424 Cr | ₹504 Cr | — |
| Net profit | ₹239 Cr | ₹187 Cr | ₹265 Cr | ₹315 Cr | ₹383 Cr | — |
| EPS (₹) | ₹6.00 | ₹5.00 | ₹6.00 | ₹7.00 | ₹8.00 | — |
| Cash from operations | ₹0 Cr | ₹99 Cr | ₹237 Cr | ₹230 Cr | ₹207 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹886 Cr | ₹1,202 Cr | ₹1,745 Cr | ₹2,065 Cr | ₹2,467 Cr | ₹3,023 Cr |
Marksans Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| Foreign institutions | 22.20% | 19.88% | 16.92% | 8.12% | 16.76% | 17.47% |
| Domestic institutions | 4.56% | 5.50% | 5.28% | 5.91% | 6.57% | 6.19% |
| Non-institutions | 29.37% | 30.75% | 33.93% | 42.09% | 32.79% | 32.47% |
Marksans Pharma vs peers
The listed Pharma & Healthcare companies nearest to Marksans Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| VIJAYAVijaya Diagnostic Centre | ₹1,382.60 | +2.04% | +42.1% | ₹14,324 Cr | 82.5 | 18.1% |
| INDGNIndegene | ₹577.95 | −1.15% | +8.6% | ₹14,171 Cr | 34.8 | 12.8% |
| NATCOPHARMNatco Pharma | ₹785.00 | +0.13% | −3.3% | ₹14,063 Cr | 9.9 | 15.4% |
| MARKSANSMarksans Pharma | ₹295.80 | −0.89% | +62.6% | ₹13,343 Cr | 32.1 | 13.8% |
| CONCORDBIOConcord Biotech | ₹1,298.00 | +1.80% | −14.6% | ₹13,294 Cr | 52.4 | — |
| CORONACORONA Remedies | ₹2,024.70 | −0.26% | — | ₹12,500 Cr | 66.8 | 24.8% |
| RAINBOWRainbow Childrens Medicare | ₹1,205.70 | −0.27% | −9.4% | ₹12,184 Cr | 43.9 | 16.9% |
Ask anything about Marksans Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against MARKSANS's own history. Try: “Why has MARKSANS moved over the last three months?” · “Backtest a 50-day moving-average crossover on MARKSANS over five years” · “Compare MARKSANS with VIJAYA on margins and valuation”
Frequently asked questions about Marksans Pharma
What is the share price of Marksans Pharma today?
Marksans Pharma (NSE: MARKSANS) last closed at ₹295.80 on 22 Oct 2026. Its 52-week high is ₹350.95 and its 52-week low is ₹155.00.
What is the market cap of Marksans Pharma?
Marksans Pharma's market capitalisation is ₹13,343 Cr (₹13,343 Cr) at the 22 Oct 2026 close, ranking 469th among the NSE companies Pivot tracks.
What is the P/E ratio of Marksans Pharma?
Marksans Pharma trades at a trailing P/E of 32.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.4.
What is the ROE and ROCE of Marksans Pharma?
Return on equity was 13.8% in FY26 and return on capital employed was 17.5% in FY26 (consolidated figures).
Is Marksans Pharma a debt-free company?
Marksans Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.
What were Marksans Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Marksans Pharma reported revenue of ₹856 Cr, +20.8% year on year, and net profit of ₹149 Cr, +64.3% year on year.
How has Marksans Pharma stock performed over the last year?
Marksans Pharma's share price has risen 62.6% over the past year, +22.2% over three months and −12.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Marksans Pharma?
As of 30 Jun 2026: promoters 43.87%, foreign institutions 17.47%, domestic institutions 6.19%, non-institutions 32.47%.
Who are Marksans Pharma's competitors?
The listed Pharma & Healthcare companies closest to Marksans Pharma by market cap are Vijaya Diagnostic Centre, Indegene, Natco Pharma, Concord Biotech, CORONA Remedies and Rainbow Childrens Medicare.
Is Marksans Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Marksans Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MARKSANS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text